Victrex/£VCT

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Victrex

Victrex PLC, founded in 1993 and headquartered in Thornton Cleveleys, UK, is a company that specializes in the manufacturing of high-performance polymeric solutions. It operates in the Specialty Chemicals sector within the materials industry, offering products made primarily from PEEK and PAEK-based materials used in a wide range of sectors including automotive, aerospace, energy, electronics, and medical. Its operations focus on both the development and production of these advanced polymer solutions, catering to both industrial and medical applications across various global markets.

Ticker

£VCT
Sector

Primary listing

LSE

Employees

1,131

Victrex Metrics

BasicAdvanced
£594M
20.06
£0.34
0.65
£0.60
8.73%

What the Analysts think about Victrex

Analyst ratings (Buy, Hold, Sell) for Victrex stock.

Bulls say / Bears say

Group sales volumes in H1 2025 increased 16% year-on-year to 2,018 tonnes, leading management to raise full-year volume growth guidance from mid- to high-single digits.
The Q3 trading update reported an 8% year-on-year increase in volumes to 1,057 tonnes, thanks to strong growth in Sustainable Solutions, especially in Energy & Industrial markets and value-added resellers.
Progress continues on developing Victrex™ PEEK as a PFAS substitute, positioning the company to benefit from regulatory restrictions on PFAS in the UK, EU, and US.
Underlying pretax profit fell 17% to £23.2m in H1 2025, while gross margin narrowed by 390 basis points to 44.1% due to foreign exchange headwinds, product mix changes, and increased costs at the China facility.
CEO Jakob Sigurdsson’s decision to retire after nearly eight years triggered a 10% drop in the share price, fueling concerns about leadership continuity.
The Q3 trading update showed a 3% decline in revenue to £71.5m, driven by lower-than-expected medical revenues and underperformance in spinal implants, indicating continued destocking in the medical segment.
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.

Victrex Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Victrex Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £VCT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs